222 related articles for article (PubMed ID: 30488605)
21. The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress.
Wang X; Wang S; Liu Y; Ding W; Zheng K; Xiang Y; Liu K; Wang D; Zeng Y; Xia M; Yang D; Wang Y
Biochem Biophys Res Commun; 2014 Mar; 446(1):160-6. PubMed ID: 24582562
[TBL] [Abstract][Full Text] [Related]
22. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
23. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
24. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
25. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
26. Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma.
Huang J; Sun C; Zhang T; Pan L; Wang S; He Q; Li D
Tumour Biol; 2014 Aug; 35(8):8193-9. PubMed ID: 24850175
[TBL] [Abstract][Full Text] [Related]
27. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
28. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
30. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
31. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
32. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.
Bendell JC; Bauer TM; Lamar R; Joseph M; Penley W; Thompson DS; Spigel DR; Owera R; Lane CM; Earwood C; Burris HA
Cancer Invest; 2016 Jul; 34(6):265-70. PubMed ID: 27379708
[TBL] [Abstract][Full Text] [Related]
33. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
35. C0818, a novel curcumin derivative, induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function.
Abdelmoaty AAA; Zhang P; Lin W; Fan YJ; Ye SN; Xu JH
Acta Pharmacol Sin; 2022 Feb; 43(2):446-456. PubMed ID: 33824458
[TBL] [Abstract][Full Text] [Related]
36. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
[TBL] [Abstract][Full Text] [Related]
37. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
[TBL] [Abstract][Full Text] [Related]
38. How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?
Wang Y; Koay YC; McAlpine SR
ChemMedChem; 2017 Mar; 12(5):353-357. PubMed ID: 28139075
[TBL] [Abstract][Full Text] [Related]
39. 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells.
Zhao S; Li H; Jiang C; Ma T; Wu C; Huo Q; Liu H
J Bioenerg Biomembr; 2015 Oct; 47(5):373-81. PubMed ID: 26323360
[TBL] [Abstract][Full Text] [Related]
40. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
